🇺🇸 FDA
Patent

US 9433686

Methods for treating castration resistant prostate cancer and metastasis by reducing B-cell number and/or function

granted A61KA61K2039/505A61K31/381

Quick answer

US patent 9433686 (Methods for treating castration resistant prostate cancer and metastasis by reducing B-cell number and/or function) held by The Regents of the University of California expires Mon Sep 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Sep 06 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
3
CPC classes
A61K, A61K2039/505, A61K31/381, A61K31/437, A61K38/1709